Table 1 |.
Baseline characteristics of the GDCN study cohort and TGNR validation cohort
| GDCN (n = 404) | TGNR (n = 557) | |
|---|---|---|
| Age (years)a | 51.4 ± 15.5 | 46.7 ± 16.7 |
| Male gender (%) | 60 | 65 |
| Race,a white (%) | 71 | 73 |
| Black | 20 | 7 |
| Asian/Others | 9 | 20 |
| Diabetes (%)a | 9 | 3 |
| Smoking | ||
| Ever (%) | 33 | 31 |
| Current (%) | 21 | NA |
| Previous history of CVE (%) | 12 | 13 |
| Serum creatinine (mg/dl)a | 1.5 ± 1.3 | 1.1 ± 0.7 |
| eGFR (ml/min/1.73 m2)a | 68.9 ± 33.5 | 78.9 ± 36.7 |
| eGFR >60 (%) | 62 | 72 |
| eGFR 45–60 (%) | 16 | 15 |
| eGFR <45 (%)a | 22 | 13 |
| Proteinuria (g/d)a | 8.7 ± 6.2 | 7.7 ± 6.6 |
| Serum albumin (g/dl) | 2.5 ± 0.8 | 2.5 ± 0.7 |
| Serum total cholesterol (mg/dl)b | 337.9 ± 107.7 | 326.9 ± 100 |
| < 200 (%) | 7 | 9 |
| 200–300 (%) | 33 | 34 |
| ≥300 (%) | 60 | 57 |
| Nephrotic syndrome (%)a | 88 | 74 |
| Medication usec | ||
| Aspirin (%) | 21 | 17 |
| Corticosteroids (%)a | 76 | 50 |
| CNI (%) | 7 | 10 |
| Cyclophosphamide (%) | 22 | 15 |
| Statin (%) | 40 | 22 |
| Follow-up duration (months)a | 24.3 (9.9–52.7) | 52 (21.3–96.2) |
Data presented as mean ± SD or median (interquartile range) for continuous variables and as percentages for categorical variables.
CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate by modified MDRD equation; GDCN, Glomerular Disease Collaborative Network; MN, membranous nephropathy; TGNR, Toronto Glomerulonephritis Registry.
Significant difference with P value <0.05 by t-test for continuous variables and χ2 test for categorical variables.
Number of patients with valid laboratory values was limited: GDCN, 270 of 404 (67%); TGNR, 341 of 557(61%).
Number of patients with valid information was limited in TGNR cohort: aspirin and statin use, 352 of 557 (63%).